Hutchmed (China) Gastric Cancer Drug Lands Priority Review Status in China

05:41 AM EST, 12/30/2025 (MT Newswires) -- Hutchmed (China) (HCM.L) said Tuesday the China National Medical Products Administration approved its new drug application for savolitinib to treat gastric cancer patients with MET amplification. The approval, which provides the drug candidate a priority review status, covers patients who have failed at least two prior systemic treatments. The decision follows the drugmaker's phase 2 registration study of savolitinib in China that met its primary endpoint of objective response rate.